Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
About this trial
This is an interventional treatment trial for Non-small Cell Lung Cancer focused on measuring NSCLC, Targretin, Retinoid, Bexarotene
Eligibility Criteria
Patients must have: Pathologic (histologic or cytologic) confirmation of NSCLC Stage IIIB with malignant pleural effusion or Stage IV disease At least one measurable or evaluable NSCLC lesion that has not been previously irradiated unless radiation therapy was more than three weeks prior to entry in the study and the lesion has been shown to have progressed subsequent to the radiation therapy ECOG performance status 0 or 1 Adequate organ system function Fasting serum triglycerides that are within the age-adjusted normal range (or normalized with appropriate intervention such as antilipid therapy prior to the initiation of Targretin capsule therapy). Patients must be able to complete at least four cycles of combination chemotherapy (i.e., approximately four months) Patients must not have had: Brain metastasis Prior chemotherapy for NSCLC Prior platinum-based chemotherapy for any indication
Sites / Locations
- Brookwood Medical Center
- Southern Arizona VA Healthcare System
- Arroyo Research Inc.
- Desert Hematology-Oncology Medical Group, Inc.
- University of Florida
- New Hope Cancer Center
- Veterans Affairs Medical Center
- Bay Area Cancer Consultants
- Northwest Medical Specialists
- Jayne Gurtler, M.D., APMC
- Louisiana State University Health Science Center
- St. Joseph Mercy Oakland Hospital
- Capitol Comprehensive Cancer Care Clinic
- SUNY Downstate Medical Center
- VA Western New York Health Care System
- Hematology-Oncology Associates
- Tariq Mahmood
- University Oncology & Hematology Associates
- Marshfield Medical Research Foundation
- Medical Associates Health Centers
- Canberra Hospital
- Port Macquarie Base Hospital
- Southern Medical Daycare Centre
- Burnside War Memorial Hospital
- Queen Elizabeth Hospital
- Royal Hobart Hospital
- Box Hill Hospital
- Border Medical Oncology
- Tom Baker Cancer Centre
- Cancer Care Manitoba
- QEII Health Sciences Center
- Ottawa Regional Cancer Centre
- Nemocnice odd. Onkologie
- Pneumologicka klinika 1. LF UK
- Klinika pneumologie a hrudni chirurgie 3.LF
- Centre Hospitalier General de Belfort
- Centre Hospitalier Francois Maillot
- Institut Jean Godinot
- Centre Hospitalier Intercommunal de la Haute-Saone
- University Hospital of Alexandroupolis
- University General Hospital of Heraklion
- 1st Pulmonary Clinic of G. Papanikolaou Hospital
- 2nd Pulmonary Clinic of G. Papanikolaou Hospital
- 6th Pneumonology Department, Sotiria Hospital for Diseases of the Chest
- 7th Pneumonology Clinic, Sotiria Hospital for Diseases of the Chest
- University Hospital of Patras
- Semmelweis University Department of Pulmonology
- Fovarosi Onkormanyzat Uzsoki utcai, Korhaza
- Koranyi National Institute for Pulmonology
- Csongrad Megyei Onkormanyzat Mellkasi
- Barzilai Medical Centre
- Hadassah Medical Center
- Meir Hospital
- Kaplan Medical Center
- Tel-Aviv Sovrasky Medical Center
- Sheba Medical Center
- Assaf Harofeh Medical Center
- Regionalne Centrum Onkologii
- Akademii Medycznej w Gdansku
- Centrum Onkologii Instytut im. M. Sklodowskiej-Curie
- Wielkopolskie Centrum Chorob Pluc I Gruzlicy
- Instytut Gruzlicy i Chorob Pluc
- Arkhangelsk Regional Oncology Center
- City Oncology Clinical Center
- Russian Oncology Research Center n.a. Blokhin
- Research Institute of Oncology n.a. Hertzen
- Central Clinical Hospital n.a. Semashko
- City Oncology Hospital #62
- City Oncology Center
- St. Petersburg Pavlov State Medical University
- Research Institute of Oncology n.a. Petrov
- Aberdeen Royal Infirmary
- Bristol Hematology and Oncology Centre
- Leicester Royal Infirmary
- Guys & St. Thomas' Cancer Centre
- Chelsea & Westminster Hospital
- University of Edinburgh